SCHEMBL14073593

SCHEMBL14073593

O=C1COc2ccc(NC(=O)c3ccc4[nH]cnc4c3)cc2N1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.58
▸ ALDH1A1 P00352 5/20 0.58
▸ POLB P06746 2/20 0.58
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ NPC1 O15118 3/20 0.56
▸ RAB9A P51151 3/20 0.56
▸ KMT2A Q03164 1/20 0.54
▸ TRPV1 Q8NER1 4/20 0.50
▸ GAA P10253 2/20 0.50
▸ SMYD3 Q9H7B4 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ CYP3A4 P08684 1/20 0.45
▸ CYP19A1 P11511 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ MALT1 Q9UDY8 1/20 0.44
▸ TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14073830 0.92 NPC1 (0.56) MAPTALDH1A1POLBSMN1; SMN2NPC1
SCHEMBL8192718 0.84 ALDH1A1 (0.77) MAPTALDH1A1POLBKMT2ATRPV1
SCHEMBL14073656 0.84 MAPT (0.64) MAPTALDH1A1POLBSMN1; SMN2NPC1
SCHEMBL14073602 0.84 ALDH1A1 (0.58) MAPTALDH1A1POLBKMT2ATRPV1
SCHEMBL14073334 0.83 TSHR (0.64) MAPTALDH1A1POLBGAASMYD3
SCHEMBL14073652 0.82 ALDH1A1 (0.61) MAPTALDH1A1POLBSMN1; SMN2NPC1
SCHEMBL14073031 0.81 ALDH1A1 (0.69) MAPTALDH1A1POLBSMN1; SMN2NPC1
SCHEMBL14073544 0.81 MAPT (0.60) MAPTALDH1A1POLBNPC1RAB9A
SCHEMBL14073640 0.80 ALDH1A1 (0.61) MAPTALDH1A1POLBKMT2ATRPV1
SCHEMBL14073692 0.79 ALDH1A1 (0.72) MAPTALDH1A1POLBSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 — — US disclosed
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety MMP12, MMP13, MMP25 MAPT 3986/4885ALDH1A1 714/4885POLB 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback